NSE: IOLCP · BSE: 524164 · ISIN INE485C01029
IOL Chemicals and Pharmaceuticals Limited stock analysis
IOL Chemicals and Pharmaceuticals Limited ranks #1214 in the TickerSutra evidence-ranked universe with a score of 55/100 and 95% data confidence. The latest captured fundamentals show ROCE of 11.3%, quarterly sales growth of 37.1% and quarterly profit growth of 89.9%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.08×
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹2,184cr | ₹257cr | ₹166cr | 12.0% |
| 2023 | ₹2,217cr | ₹227cr | ₹140cr | 10.0% |
| 2024 | ₹2,133cr | ₹232cr | ₹135cr | 11.0% |
| 2025 | ₹2,079cr | ₹202cr | ₹101cr | 10.0% |
| 2026 | ₹2,319cr | ₹270cr | ₹138cr | 12.0% |
| TTM | ₹2,524cr | ₹310cr | ₹168cr | 12.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
RoutineKey licenses/regulatory approvals (Sub-para 12-Para B)NSE · 25 Sept 2026 · Structured filingIOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Key licenses/regulatory approvals (Sub-para 12-Para B)
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Key licenses/regulatory approvals (Sub-para 12-Para B)
Open original XBRL sourceIOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
RoutineIOL Chemicals & Pharmaceuticals Ltd - 524164 - Grant Of Certificate Of Suitability (CEP) For Fenofibrate - Process IIBSE · 25 Sept 2026CEP for Fenofibrate - Process II
RoutineTrading WindowBSE · 25 Sept 2026IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineKey licenses/regulatory approvals (Sub-para 12-Para B)NSE · 23 Sept 2026 · Structured filingIOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Key licenses/regulatory approvals (Sub-para 12-Para B)
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Key licenses/regulatory approvals (Sub-para 12-Para B)
Open original XBRL sourceMANAGEMENT COMMENTARY
Signals from filed documents
So we are foreseeing good demand in paracetamol. Sir, my next question is, given the sharp rise in ethyl acetate and acetic anhydride prices following the U.S.-Iran war, could you please update on the current pricing environment for both these products? Rakesh Mahajan: Due to war, the prices were increased substantially in the month of March itself, but after that it is stable to some extent.
Pardeep Kumar Khanna: So, Maulik, both top line and bottom -line growth was due to higher volumes along with better pricing of our established products as well as growth in new products. Also in spite of increase in input prices, we are able to achieve these numbers by passing the increased cost to customers due to healthy demand, both in domestic and export markets. So, these are the main reasons for growth in both
PAT margin consequently improved to 8.4 percentage compared with 6.1 percentage in quarter one of financial year ‘26. The improvement in profitability reflects the benefit of higher operating leverage, better capacity utilization, improved product mix, and continued focus on operational efficiencies. Our export contribution also increased to 28.5% of revenue compared with 24.4% in same quarter of last financial year,
So going forward, the growth what we looking is the broad-based growth involving all product portfolio with better product mix. My second question would be, the company has been strengthening its backward integration manufacturing platform. Are there any specific intermediates, KSMs currently being evaluated for backward integration that could meaningfully improve product economics?
Pardeep Kumar Khanna: Jainam ji, we follow a capex of approximately INR200 crores every year, which is planned with a long term view to s upport sustainable growth. Out of total capex planned, 60% is directed towards expansion and new product . And the remaining 40% goes to infrastructure, improvements for better efficiencies and reduction in cost.
While ibuprofen remains an important part of our portfolio, our strategic focus is increasingly on building IOL as a diversified and integrated API platform, with multiple products contributing to our growth. Our international business also strengthened during the quarter, with exports increasing to about 28.5% of revenue, while the NMPA approval for clopidogrel in China further expands our regulatory reach and marke
At the same time, we will continue to maintain a disciplined approach towards capital allocation and investments with a focus on projects offering attractive long-term returns. IOL Chemicals and Pharmaceuticals Limited August 13, 2026 Page 4 of 15 For financial year 27, we remain confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 2
Abhay Raj Singh: So basically, our all the products got CEP approval, and apart from CEP approval for all products, we have also got approval from the US FDA for our five products and another two, three products are already line d up as the formulators ha ve filed their ANDA. So once their ANDA is approved, our products will also get approval from US FDA, CEP is available for all the product. Kushal Kumar Rana: And a
Pardeep Kumar Khanna: Sure, we expect. And I mean in terms of our regulated market exports, so any new products which we have filed or you know are awaiting approval anything, sir, any visibility on that? Abhay Raj Singh: So basically, our all the products got CEP approval, and apart from CEP approval for all products, we have also got approval from the US FDA for our five products and another two, three products are
And also one question is sequentially, we've seen a decline in gross margin. So, is my assumption correct that last quarter, we had some inventory gains because of which our gross profit was higher -- gross margin was higher, and this quarter due to higher input costs the gross margins were relatively lower on a sequential basis? In just I have already explained to some analyst that in the March quarter we in a for f
So these are some of the variables which can lead to the export number a little bit up and down. Sir, are we planning further regulatory approvals for Chemical segment or for other product approval in Chemical segment? IOL Chemicals and Pharmaceuticals Limited August 13, 2026 Page 13 of 15 Abhay Raj Singh: So we have basically 2 products.
Abu Rafe: Thank you for giving me the opportunities . So my first question is, given that paracetamol has seen a relatively weak demand over the past few years, what is the current outlook for paracetamol, sir? Abhay Raj Singh: So the paracetamol for the IOL, we started around two years back, with 3,600 MTPA capacity which we tripled last year.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…